Scalp Psoriasis
SORILUX Foam delivers effective, steroid-free treatment for scalp psoriasis
SORILUX Foam was evaluated as monotherapy for treatment of moderate plaque psoriasis of the scalp in a multicenter, randomized, double-blind, vehicle-controlled study in 363 patients aged 12 to 97 years (11 patients were <18 years). 1
Study design 2
- At baseline, patients were required to have ≥10% involvement of the total scalp surface area with an Investigator’s Static Global Assessment (ISGA) score of 3 (moderate) on a 6-point scale for erythema, thickness, and scaliness
- Patients were instructed to self-administer SORILUX Foam or vehicle foam as monotherapy twice daily, morning and evening, for 8 weeks
Treatment success was defined as an ISGA score of 0 (clear) or 1 (almost clear) at week 8. 3
Think you know calcipotriene? Look again.
SORILUX Foam—photos from clinical trials
![Baseline And 8 Weeks Scalp Results Photo Of An Actual Patient Who Achieved Treatment Success With SORILUX Foam](/sites/all/themes/sorilux/images/SOR-Mobile/5.1-HCP-Scalp-baseline-mobile.png)
![Baseline And 8 Weeks Scalp Results Photo Of An Actual Patient Who Achieved Treatment Success With SORILUX Foam](/sites/all/themes/sorilux/images/SOR-Mobile/5.1-HCP-Scalp-week8-mobile.png)
Actual patient from clinical trials with moderate plaque psoriasis (ISGA score 3) at baseline, representative of patients who achieved treatment success. Individual results may vary.
In a Phase III clinical study of moderate-severity scalp psoriasis, SORILUX Foam monotherapy achieved significant results when compared with vehicle foam 1
At week 8, 41% of patients treated with SORILUX Foam achieved treatment success compared with 24% of patients treated with vehicle foam ( P<0.001). 1
SORILUX Foam was well tolerated. The rate of adverse events was similar to that of vehicle foam.
APPLICATION SITE REACTIONS FROM THE PIVOTAL STUDY FOR PLAQUE PSORIASIS OF THE SCALP 2
ADVERSE EVENTS REPORTED IN >2% OF PATIENTS | SORILUX FOAM (N=181) |
VEHICLE FOAM (N=182) |
---|---|---|
Application site pain | 4% | 3% |
Application site pruritus | 4% | 4% |
Application site erythema | 3% | 0% |
References: 1. Feldman SR, Eastman WJ, Brundage T, Mills M. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol. 2013;12(3):300-306. 2. Data on file. Greenville, NC; Mayne Pharma LLC. 3. SORILUX Foam [package insert]. Greenville, NC: Mayne Pharma; 2019.